cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.5455480.v1
title: MarcioFialho_PTASE_results_2017.zip

description: Outputs from program PTASE, used in Marcio Fialho's doctorate thesis.<br><br>Reference:<br>FIALHO, M. A. A. Improved star identification techniques for monochrome and color star trackers. 2017. 246p. Doctorate Thesis - Instituto Nacional de Pesquisas Espaciais, Sao Jose dos Campos, 2017.<br>
DOI: 10.6084/m9.figshare.5455447.v1
title: Motion_coherence_thresholds

description: For both experiments, the motion coherence threshold for each observer across conditions.
DOI: 10.6084/m9.figshare.5455360
title: Cover crop residue management : crop and soil raw data (2012-2016)

description: Data from two field experiments held in the experimental farm of Gembloux Agr-Bio Tech (ULiège) from 2012-2015 for field 1 and 2013-2016 for field 2. <br><br>CT = conventional tillage<br>RT = reduced tillage<br><br>ST = strip tillage<br>DST = decompaction and shallow tillage<br>SP = spring ploughing<br>WP = winter ploughing<br>
DOI: 10.6084/m9.figshare.5455360.v1
title: Cover crop residue management : crop and soil raw data (2012-2016)

description: Data from two field experiments held in the experimental farm of Gembloux Agr-Bio Tech (ULiège) from 2012-2015 for field 1 and 2013-2016 for field 2. <br><br>CT = conventional tillage<br>RT = reduced tillage<br><br>ST = strip tillage<br>DST = decompaction and shallow tillage<br>SP = spring ploughing<br>WP = winter ploughing<br>
DOI: 10.6084/m9.figshare.5455246
title: Jobs Posts up to September 30th 2017

description: List of Jobs Posts across several job application sites, until September 2017
DOI: 10.6084/m9.figshare.5455246.v2
title: Jobs Posts up to September 30th 2017

description: List of Jobs Posts across several job application sites, until September 2017
DOI: 10.6084/m9.figshare.5455246.v1
title: Jobs Posts up to September 30th 2017

description: List of Jobs Posts across several job application sites, until September 2017
DOI: 10.6084/m9.figshare.5455150
title: Supplementary Material for: Proteinuria and Glomerular Damage in Rab3A Knockout Mice Chronically Fed a High-Glucose Diet

description: <i>Background/Aims:</i> The relative contribution of genetic factors and dietary patterns to glomerular damage in healthy individuals and prediabetic conditions is currently unclear. All Rab3A knockout (KO) mice spontaneously develop macroalbuminuria, but only male mice exhibit a glucose-intolerant phenotype, thus making the model suitable to examine the impact of a diet on preexisting podocyte damage. <i>Methods:</i> Male and female Rab3A KO and wild-type (WT) mice were chronically fed a high-glucose diet (HGD). Biochemical tests, histology and immunohistochemistry were periodically performed whilst primary podocytes served for in vitro analyses. <i>Results:</i> Chronic administration of an HGD did not induce de novo alterations in WT kidneys but caused progressive worsening of podocyte and glomerular damage in both male and female Rab3A KO. Though glomerular lesions, reminiscent of human diabetic nephropathy, were more severe in male mice, overt proteinuria and renal damage were also evident in female mice. The in vitro analysis of Rab3A WT and KO podocytes revealed diminished actin plasticity in the cell processes of KO podocytes. Furthermore, a modest increase in glucose concentration induced profound cytoskeletal changes only in Rab3A KO cells. <i>Conclusions:</i> Our data show that chronic administration of an HGD to Rab3A KO mice that have a genetic defect that impairs podocyte actin plasticity results in increased podocyte damage and leads to overt proteinuria. If the same diet is given to male Rab3A KO animals, with additionally altered glucose homeostasis, this results in renal lesions similar to those of human diabetic nephropathy.
DOI: 10.6084/m9.figshare.5455138
title: Supplementary Material for: Role of Epidermal Growth Factor Receptor Expression on Patient Survival in Pancreatic Cancer: A Meta-Analysis

description: <i>Background/Aims:</i> Epidermal growth factor receptor (EGFR) has been considered as an attractive and potential therapeutic target of pancreatic cancer. However, the clinical importance of EGFR expression remains controversial. <i>Methods:</i> We performed a meta-analysis of previous studies to quantitatively review the effects of EGFR expression on survival in patients with pancreatic cancer. <i>Results:</i> Eight studies (570 patients) were included to perform a meta-analysis of the survival results. Overall, positivity for EGFR expression was 45.1% in pancreatic carcinoma. The combined hazard ratio was 1.225 (95% CI 1.014–1.481; p = 0.035), indicating that EGFR expression has a significant impact on survival. Heterogeneity was absent between studies and publication bias, which suggests that the summary statistics obtained may approximate the actual average. Three trials reported a survival disadvantage for patients with EGFR expression while five trials reported no statistically significant difference. <i>Conclusion:</i> EGFR expression is a poor prognostic factor for survival in patients with pancreatic cancer.
DOI: 10.6084/m9.figshare.5455138.v1
title: Supplementary Material for: Role of Epidermal Growth Factor Receptor Expression on Patient Survival in Pancreatic Cancer: A Meta-Analysis

description: <i>Background/Aims:</i> Epidermal growth factor receptor (EGFR) has been considered as an attractive and potential therapeutic target of pancreatic cancer. However, the clinical importance of EGFR expression remains controversial. <i>Methods:</i> We performed a meta-analysis of previous studies to quantitatively review the effects of EGFR expression on survival in patients with pancreatic cancer. <i>Results:</i> Eight studies (570 patients) were included to perform a meta-analysis of the survival results. Overall, positivity for EGFR expression was 45.1% in pancreatic carcinoma. The combined hazard ratio was 1.225 (95% CI 1.014–1.481; p = 0.035), indicating that EGFR expression has a significant impact on survival. Heterogeneity was absent between studies and publication bias, which suggests that the summary statistics obtained may approximate the actual average. Three trials reported a survival disadvantage for patients with EGFR expression while five trials reported no statistically significant difference. <i>Conclusion:</i> EGFR expression is a poor prognostic factor for survival in patients with pancreatic cancer.
DOI: 10.6084/m9.figshare.5455117
title: Supplementary Material for: Metanephros Transplantation Inhibits the Progression of Vascular Calcification in Rats with Adenine-Induced Renal Failure

description: <i>Background/Aim:</i> Recent research has shown that transplanted metanephroi form primitive vascularized kidneys with histologically recognizable renal features. The aim of the present study was to determine the metabolic function of transplanted metanephroi in rats with chronic renal failure (CRF), with particular reference to secondary hyperparathyroidism and vascular calcification. <i>Methods:</i> CRF was induced in 11-week-old male Wistar rats by maintaining them on a 0.75% adenine diet for 4 weeks, followed by normal diet for an additional 2 weeks. At the end of adenine loading, whole metanephroi from embryonic day 15 rats were transplanted into the omentum and epididymis of the transplantation group. Vascular calcification was evaluated 2 weeks after metanephroi transplantation. <i>Results:</i> Metanephros transplantation significantly reduced vascular calcium and phosphorus content and suppressed the progression of vascular calcification as indicated by von Kossa staining of the media of the thoracic aorta. However, no significant differences between the adenine-fed control and transplantation groups were found regarding the serum levels of 1,25(OH)<sub>2</sub>D<sub>3</sub>, calcium or phosphorus or the calcium × phosphorus product. <i>Conclusion:</i> The present study has shown that transplantation of metanephroi suppresses the progression of vascular calcification via a mechanism that is independent of calcium-phosphorus dynamics.
DOI: 10.6084/m9.figshare.5455111
title: Supplementary Material for: Elevated microRNA miR-21 Levels in Pancreatic Cyst Fluid Are Predictive of Mucinous Precursor Lesions of Ductal Adenocarcinoma

description: <i>Background:</i> Biomarkers for the diagnostic classification of pancreatic cysts are urgently needed. Deregulated microRNA (miRNAs) expression is widespread in pancreatic cancer. We assessed whether aberrant miRNAs in pancreatic cyst fluid could be used as potential biomarkers for cystic precursor lesions of pancreatic cancer. <i>Methods:</i> Cyst fluid specimens were prospectively collected from 40 surgically resected pancreatic cysts, and small RNAs were extracted. The ‘mucinous’ cohort included 14 intraductal papillary mucinous neoplasms (including 3 with an associated adenocarcinoma) and 10 mucinous cystic neoplasms; the ‘nonmucinous’ cohort included 11 serous cystadenomas and 5 other benign cysts. Quantitative reverse transcription PCR was performed for five miRNAs (miR-21, miR-155, miR-221, miR-17-3p, miR-191), which were previously reported as overexpressed in pancreatic adenocarcinomas. <i>Results:</i> Significantly higher expression of miR-21, miR-221, and miR-17-3p was observed in the mucinous versus nonmucinous cysts (p &lt; 0.01), with the mean relative fold differences being 7.0-, 7.9-, and 5.4-fold, respectively. Receiver operating characteristic curves demonstrated the highest median area under the curve for miR-21, with a median specificity of 76%, at a sensitivity of 80%. <i>Conclusion:</i> This pilot study demonstrates that profiling miRNAs in pancreatic cyst fluid samples is feasible and can yield potential biomarkers for the classification of cystic lesions of the pancreas.
DOI: 10.6084/m9.figshare.5455057
title: Supplementary Material for: Pancreatic Stellate Cell Models for Transcriptional Studies of Desmoplasia-Associated Genes

description: <i>Background:</i> Pancreatic stellate cells are emerging as key players in pathophysiopathological processes underlying the development of pancreatic disease, including pancreatitis and cancer. The cells are scarce in the pancreas making their isolation time and resource use consuming. <i>Methods:</i> Therefore, with the ultimate goal of facilitating mechanistic studies, here we report the isolation, characterization, and immortalization of stellate cell lines from rat and mouse origin. <i>Results:</i> These cell lines display morphological and molecular markers as well as non-tumorigenic characteristics similar to the frequently used hepatic counterparts. In addition, we have tested their robustness as a model for transcriptional regulatory studies. We find that these cells respond well to TGFβ signaling by triggering a distinct cascade of gene expression, some genes overlap with the TGFβ response of LX2 cells. These cells express several key chromatin proteins and epigenetic regulators involved in the regulation of gene expression, including co-repressors such as Sin3A (short-term repression), HP1 (long-term repression), as well as CBP/p300 (activation). Furthermore, these cells are well suited for Gal4-based transcriptional activation and repression assays. <i>Conclusions:</i> The cell model reported here may therefore help fuel investigations in the field of signaling, transcription, and perhaps other studies on similarly exciting cellular processes.
DOI: 10.6084/m9.figshare.5455066
title: Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab

description: <b>Background:</b> Ixekizumab is a high-affinity monoclonal antibody that selectively targets interleukin-17 A. <b>Objective:</b> Examine the efficacy of ixekizumab in clearing psoriasis within different body regions. <b>Methods:</b> Data from 3 placebo- (PBO) or PBO- and etanercept (ETN)-controlled trials were integrated. Patients with moderate-to-severe psoriasis were randomized to 12 weeks of PBO (UNCOVER-1, -2, -3, <i>N</i> = 792; UNCOVER-2, -3, <i>N</i> = 361), 50 mg ETN twice weekly (<i>N</i> = 740), or 80 mg ixekizumab every 2 (IXE Q2W; <i>N</i> = 1169; <i>N</i> = 736) or 4 weeks (IXE Q4W; <i>N</i> = 1165; <i>N</i> = 733) after a 160-mg starting dose. <b>Results:</b> Mean percent improvements in regional Psoriasis Area and Severity Index (PASI) were noted at Week 1 and increased through Week 12 in the IXE Q2W (approved dosing regimen) group for each body region. Week 12 improvements were 91.4% (head/neck); 92.8% (trunk); 89.9% (arms); and 88.7% (legs) (all regions <i>p</i> p &lt; .001). Scaling and thickness reduced faster than erythema. <b>Conclusions:</b> Within 12 weeks of ixekizumab treatment, all signs of psoriasis across all body regions reached clinically meaningful improvements, with the head/neck and trunk responding quicker than psoriasis of the arms and legs, especially with reduced scaling and thickness.
DOI: 10.6084/m9.figshare.5455048
title: Supplementary Material for: Idiopathic Duct-Centric Pancreatitis: Disease Description and Endoscopic Ultrasonography-Guided Trucut Biopsy Diagnosis

description: <i>Background/Aims:</i> Recent data demonstrate the presence of two autoimmune pancreatitis (AIP) subtypes. All existing endoscopic ultrasonography-guided trucut biopsy (EUS-TCB) data pertain to type 1 disease. Our aim is to determine if EUS-TCB samples are sufficient for diagnosing type 2 AIP. <i>Methods:</i> This is a retrospective case series conducted in an academic tertiary care center. Patients included those with type 2 AIP (n = 5), retrospectively identified from a database of all patients with AIP, diagnosed by HISORt criteria (n = 125). The primary outcome measure was the diagnostic capability of EUS-TCB for type 2 AIP. <i>Results:</i> 5 patients (4 male, 1 female; mean age 39.6 years) who underwent EUS-TCB were diagnosed with type 2 AIP. The serum IgG<sub>4</sub> level was elevated in 1 of the 4 patients tested. CT/MRI revealed diffuse pancreas enlargement (n = 3), a pancreas head mass (n = 1), and a normal pancreas (n = 1). Prior to EUS, AIP was not specifically suspected, but part of a broad differential (n = 3) or not suspected at all (n = 2). Fine-needle aspiration was negative for neoplasia and AIP. The TCB histology was definitive (n = 4) or suggestive (n = 1) for type 2 AIP. No complications developed. <i>Conclusions:</i> EUS-TCB may be safe and may provide sufficient material to definitively diagnose type 2 AIP.
DOI: 10.6084/m9.figshare.5455066.v1
title: Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab

description: <b>Background:</b> Ixekizumab is a high-affinity monoclonal antibody that selectively targets interleukin-17 A. <b>Objective:</b> Examine the efficacy of ixekizumab in clearing psoriasis within different body regions. <b>Methods:</b> Data from 3 placebo- (PBO) or PBO- and etanercept (ETN)-controlled trials were integrated. Patients with moderate-to-severe psoriasis were randomized to 12 weeks of PBO (UNCOVER-1, -2, -3, <i>N</i> = 792; UNCOVER-2, -3, <i>N</i> = 361), 50 mg ETN twice weekly (<i>N</i> = 740), or 80 mg ixekizumab every 2 (IXE Q2W; <i>N</i> = 1169; <i>N</i> = 736) or 4 weeks (IXE Q4W; <i>N</i> = 1165; <i>N</i> = 733) after a 160-mg starting dose. <b>Results:</b> Mean percent improvements in regional Psoriasis Area and Severity Index (PASI) were noted at Week 1 and increased through Week 12 in the IXE Q2W (approved dosing regimen) group for each body region. Week 12 improvements were 91.4% (head/neck); 92.8% (trunk); 89.9% (arms); and 88.7% (legs) (all regions <i>p</i> p &lt; .001). Scaling and thickness reduced faster than erythema. <b>Conclusions:</b> Within 12 weeks of ixekizumab treatment, all signs of psoriasis across all body regions reached clinically meaningful improvements, with the head/neck and trunk responding quicker than psoriasis of the arms and legs, especially with reduced scaling and thickness.
DOI: 10.6084/m9.figshare.5455006
title: Neuromuscular performance - Influence of platinum harmonized textile on neuromuscular, systemic and subjective recovery.xlsx

description: Neuromuscular performance data in terms of torque data
DOI: 10.6084/m9.figshare.5455000
title: Jump performance - Influence of platinum harmonized textile on neuromuscular, systemic and subjective recovery.xlsx

description: Jump performance data. Counter-movement and Drop Jump data
DOI: 10.6084/m9.figshare.5455003
title: Subjective parameters - Influence of platinum harmonized textile on neuromuscular, systemic and subjective recovery.xlsx

description: Subjective data (pain intensity, recovery condition, sleep quality and sleep duration).
DOI: 10.6084/m9.figshare.5454997
title: Biochemical markers - Influence of platinum harmonized textile on neuromuscular, systemic and subjective recovery.xlsx

description: Biochemical marker creatinkinase
DOI: 10.6084/m9.figshare.5455003.v1
title: Subjective parameters - Influence of platinum harmonized textile on neuromuscular, systemic and subjective recovery.xlsx

description: Subjective data (pain intensity, recovery condition, sleep quality and sleep duration).
DOI: 10.6084/m9.figshare.5454967
title: Small leucine-rich repeat proteoglycans associated with mature insoluble elastin serve as binding sites for galectins

description: We previously reported that galectin-9 (Gal-9), an immunomodulatory animal lectin, could bind to insoluble collagen preparations and exerted direct cytocidal effects on immune cells. In the present study, we found that mature insoluble elastin is capable of binding Gal-9 and other members of the human galectin family. Lectin blot analysis of a series of commercial water-soluble elastin preparations, PES-(A) ~ PES-(E), revealed that only PES-(E) contained substances recognized by Gal-9. Gal-9-interacting substances in PES-(E) were affinity-purified, digested with trypsin and then analyzed by reversed-phase HPLC. Peptide fragments derived from five members of the small leucine-rich repeat proteoglycan family, versican, lumican, osteoglycin/mimecan, prolargin, and fibromodulin, were identified by N-terminal amino acid sequence analysis. The results indicate that Gal-9 and possibly other galectins recognize glycans attached to small leucine-rich repeat proteoglycans associated with insoluble elastin and also indicate the possibility that mature insoluble elastin serves as an extracellular reservoir for galectins. The members of galectin family, especially galectin-9, recognize small leucine-rich repeat.
DOI: 10.6084/m9.figshare.5454982
title: What's Good About Big Pupils?

description: These slides were presented (with very minor variations) at the following conferences: ECEM 2017, ESCoP 2017, and the 2017 International Pupil Colloquium
DOI: 10.6084/m9.figshare.5454967.v1
title: Small leucine-rich repeat proteoglycans associated with mature insoluble elastin serve as binding sites for galectins

description: We previously reported that galectin-9 (Gal-9), an immunomodulatory animal lectin, could bind to insoluble collagen preparations and exerted direct cytocidal effects on immune cells. In the present study, we found that mature insoluble elastin is capable of binding Gal-9 and other members of the human galectin family. Lectin blot analysis of a series of commercial water-soluble elastin preparations, PES-(A) ~ PES-(E), revealed that only PES-(E) contained substances recognized by Gal-9. Gal-9-interacting substances in PES-(E) were affinity-purified, digested with trypsin and then analyzed by reversed-phase HPLC. Peptide fragments derived from five members of the small leucine-rich repeat proteoglycan family, versican, lumican, osteoglycin/mimecan, prolargin, and fibromodulin, were identified by N-terminal amino acid sequence analysis. The results indicate that Gal-9 and possibly other galectins recognize glycans attached to small leucine-rich repeat proteoglycans associated with insoluble elastin and also indicate the possibility that mature insoluble elastin serves as an extracellular reservoir for galectins. The members of galectin family, especially galectin-9, recognize small leucine-rich repeat.
DOI: 10.6084/m9.figshare.5454964
title: Nano-sized zinc oxide and silver, but not titanium dioxide, induce innate and adaptive immunity and antiviral response in differentiated THP-1 cells

description: Nano-sized metal oxides are currently the most manufactured nanomaterials (NMs), and are increasingly used in consumer products. Recent exposure data reveal a genuine potential for adverse health outcomes for a vast array of NMs, however the underlying mechanisms are not fully understood. To elucidate size-related molecular effects, differentiated THP-1 cells were exposed to nano-sized materials (n-TiO<sub>2,</sub> n-ZnO and n-Ag), or their bulk-sized (b-ZnO and b-TiO<sub>2</sub>) or ionic (i-Ag) counterparts, and genome-wide gene expression changes were studied at low-toxic concentrations (&lt;15% cytotoxicity). TiO<sub>2</sub> materials were nontoxic in MTT assay, inducing only minor transcriptional changes. ZnO and Ag elicited dose-dependent cytotoxicity, wherein ionic and particulate effects were synergistic with respect to n-ZnO-induced cytotoxicity. In gene expression analyzes, 6 h and 24 h samples formed two separate hierarchical clusters. N-ZnO and n-Ag shared only 3.1% and 24.6% differentially expressed genes (DEGs) when compared to corresponding control. All particles, except TiO<sub>2</sub>, activated various metallothioneins. At 6 h, n-Zn, b-Zn and n-Ag induced various immunity related genes associating to pattern recognition (including toll-like receptor), macrophage maturation, inflammatory response (TNF and IL-1beta), chemotaxis (CXCL8) and leucocyte migration (CXCL2-3 and CXCL14). After 24 h exposure, especially n-Ag induced the expression of genes related to virus recognition and type I interferon responses. These results strongly suggest that in addition to ionic effects mediated by metallothioneins, n-Zn and n-Ag induce expression of genes involved in several innate and adaptive immunity associated pathways, which are known to play crucial role in immuno-regulation. This raises the concern of safe use of metal oxide and metal nanoparticle products, and their biological effects.
DOI: 10.6084/m9.figshare.5454952
title: Ligand-based virtual screening, molecular docking, QSAR and pharmacophore analysis of quercetin-associated potential novel analogs against epidermal growth factor receptor

description: The present study was to explore expectation and examination of therapeutic potential quercetin analogs as efficient anticancer agents against human epidermal growth factor receptor (EGFR), which is a consistent hallmark for moderating the non-small-cell lung carcinoma (NSCLC). Here, ligand-based virtual screening, pharmacophore approach and molecular docking were established as rational strategies for recognition of small analogs against the ligand binding domain of EGFR (PDB code: 1XKK). Adverse effects, toxicogenomics and pharmacokinetics reported that 10 candidates showed reliable consequences with less side effects and more efficient for target receptor. Protein–ligand interaction profiles revealed that the probable H-bonds, atomic-π contacts, salt bridges and van der Waals interactions sustain the complexity and stability of receptor structure; thus, they could complicate to generate single alteration acquired for drug resistance. <i>In silico</i> anticancer properties explain the lead scaffolds which are assumed to be flexible and experimentally proved chemicals. The overall consequences indicated that recognized leads could be utilized as reference skeletons for new inhibitors envisaging toward EGFR to ameliorate NSCLC and other malignant disorders.